De Novo myelodysplastic syndromes in patients 20-50 years old are enriched for adverse risk features

Data concerning the treatment approach and clinical outcomes in younger patients with myelodysplastic syndromes (MDS) are lacking. Furthermore, published results from genomic profiling in the young adult MDS population are few. We identified patients aged 20-50 at diagnosis evaluated for de novo MDS at our institution over a 32-year period. Clinical information and results from sequencing panels were extracted for analysis. 68 eligible patients were found, including 32% with multilineage dysplasia and 29% with excess blasts-2 WHO subtypes. Revised International Prognostic Scoring System for MDS (IPSS-R) categorization had 47% high/very high-risk, and this classification held prognostic significance. The median overall survival was 59 months, and most patients (75%) underwent allogeneic hematopoietic cell transplantation (alloHCT). Thirty-four patients had mutational profiling; the most commonly mutated gene was TP53 and most commonly altered gene category was epigenetic regulators. Younger patients with de novo MDS represented a unique subset with high-risk disease features (adverse cytogenetics, higher R-IPSS) frequently observed along with alterations in TP53 and genes related to epigenetic and transcription pathways.

Automated summary

There is a lack of data on the treatment approach and clinical outcomes in younger patients with myelodysplastic syndromes (MDS), particularly in terms of genomic profiling. This study analyzed patients aged 20-50 at diagnosis and found that younger patients with de novo MDS often have high-risk disease features, including adverse cytogenetics, higher R-IPSS, and alterations in genes related to epigenetic and transcription pathways.